New drug trial aims to stop deadly head & neck cancer from coming back
NCT ID NCT07303283
Summary
This study compares two different drugs given after initial cancer treatment to prevent the cancer from returning in patients with advanced nasopharyngeal carcinoma (a type of head and neck cancer). About 218 patients who have completed their main cancer treatment will receive either a newer intravenous drug called Becotatug Vedotin for three cycles or an oral chemotherapy drug called capecitabine for one year. Researchers will track which treatment better prevents cancer recurrence and causes fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.